Ute Egerland

This inventor holds 22 USPTO granted patents and 2 published patent applications and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Elbion Ag, Arzneimittelwerk Dresden Gmbh, Janssen Pharmaceuticals, Inc.. Active years: 2001-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ute Egerland. Retrieved from https://idiyas.com/inventor/ute-egerland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 2)

% Patents Active = 31.8

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 7.3

ph-index = 8

Forward Citations = 136(Granted Patents)

Location History:

Radebavl, DE (2004)
Radebeul, DE (2001 - 2023)

Company Filing History:

Arzneimittelwerk Dresden Gmbh

patents

4 out of 161

Janssen Pharmaceuticals, Inc.

patents

4. 2 out of 28

Biotie Therapies Corporation

Boehringer Ingelheim International Gmbh

where one patent can have more than one assignee

Years Active: 2001-2023

Loading Chart...

Areas of Expertise:

Pyrazoles

Triazoles

NR2B Receptor Inhibitors

Phosphodiesterase 4

Phosphodiesterase 10

7-Azaindoles

Hydroxyindoles

CNS Disorders

Therapeutic Agents

Synthesis Methods

Erectile Dysfunction

Neurological Disorders

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE49517 - Pyrazoles (2023-05-01),

2. 10323021 - Triazoles as NR2B receptor inhibitors (2019-06-18),

3. 10155727 - Pyrazoles (2018-12-18),

4. 9981950 - Triazoles as NR2B receptor inhibitors (2018-05-29),

5. 9085584 - Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders (2015-07-21),

6. 7947705 - 7-azaindoles and the use thereof as therapeutic agents (2011-05-24),

7. 7875618 - Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders (2011-01-25),

8. 7683074 - 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them (2010-03-23),

9. 7550465 - Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them (2009-06-23),

10. 7419987 - 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them (2008-09-02),

11. 7211583 - 7-azaindoles and the use thereof as therapeutic agents (2007-05-01),

12. 7169787 - 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same (2007-01-30),

13. 7166637 - Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them (2007-01-23),

14. 7161009 - Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation (2007-01-09),

15. 7067536 - 4-,6- or 7-hydroxyindoles with N-oxide groups and the use thereof as therapeutic agents (2006-06-27),

Title: Ute Egerland: Pioneering Sustainable Tech Innovations

Introduction

Ute Egerland, a visionary inventor based in Radebeul, DE, has made remarkable strides in the field of technology with 22 patents to his name. His relentless drive for innovation and commitment to building a more sustainable future continue to shape the world of technology.

Latest Patents

Among his latest patents, Ute Egerland has delved into groundbreaking research on Pyrazoles - potent NMDA NR2B receptor inhibitors that hold promise for treating a range of central nervous system diseases. Additionally, his work on Triazoles as NR2B receptor inhibitors showcases his dedication to exploring novel compounds for treating disorders mediated by GluN2B receptors.

Career Highlights

Throughout his career, Ute Egerland has been associated with esteemed companies like Elbion AG and Arzneimittelwerk Dresden GmbH. His innovative contributions have not only propelled these companies forward but have also solidified his reputation as a pioneering force in the tech industry.

Collaborations

Ute Egerland's impact extends beyond his individual achievements, as he has collaborated closely with industry peers such as Norbert Höfgen and Degenhard Marx. These partnerships have not only fueled innovation but have also fostered a culture of collaboration and knowledge-sharing within the tech community.

Conclusion

In conclusion, Ute Egerland's unwavering passion for innovation and his relentless pursuit of sustainable tech solutions continue to inspire and shape the landscape of technology. His inventiveness, coupled with his dedication to creating impactful change, cements his legacy as a true trailblazer in the world of tech innovation.

Profile summary based on public USPTO records.